Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery.

Bioconjugate chemistry·2015
Same author

A bioreactor system for in vitro tendon differentiation and tendon tissue engineering.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2015
Same author

A silk-based encapsulation platform for pancreatic islet transplantation improves islet function in vivo.

Journal of tissue engineering and regenerative medicine·2015
Same author

Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2015
Same author

Silk macromolecules with amino acid-poly(ethylene glycol) grafts for controlling layer-by-layer encapsulation and aggregation of recombinant bacterial cells.

ACS nano·2015
Same author

Biomineralization of stable and monodisperse vaterite microspheres using silk nanoparticles.

ACS applied materials & interfaces·2015

Related Experiment Video

Updated: May 9, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.

Rebecca L Williams-Karnesky1, Ursula S Sandau, Theresa A Lusardi

  • 1RS Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon 97232, USA.

The Journal of Clinical Investigation
|July 19, 2013
PubMed
Summary

Adenosine, a natural brain compound, reverses DNA methylation changes linked to epilepsy. This epigenetic therapy in rats halted epilepsy progression by inhibiting DNA methylation, offering a new treatment strategy.

More Related Videos

Targeted Knockdown of Genes in the Choroid Plexus
04:43

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
09:46

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

Published on: March 8, 2015

Related Experiment Videos

Last Updated: May 9, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Targeted Knockdown of Genes in the Choroid Plexus
04:43

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
09:46

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

Published on: March 8, 2015

Area of Science:

  • Neuroscience
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic modifications, such as DNA methylation, alter gene expression and neuronal excitability, potentially driving epileptogenesis.
  • Adenosine, an endogenous anticonvulsant, has a newly identified epigenetic role in regulating DNA methylation.
  • Reversing epigenetic changes offers a potential therapeutic strategy for epilepsy.

Purpose of the Study:

  • To investigate the epigenetic function of adenosine in DNA methylation and its role in epileptogenesis.
  • To determine if inhibiting DNA methylation can prevent or treat epilepsy.
  • To assess the therapeutic potential of adenosine augmentation for epilepsy.

Main Methods:

  • Investigated adenosine's effect on DNA methylation through interference with the transmethylation pathway.
  • Utilized a rat model of temporal lobe epilepsy to study hippocampal DNA methylation, DNA methyltransferase activity, and adenosine homeostasis.
  • Employed bioengineered silk implants for sustained delivery of adenosine to the brains of epileptic rats.

Main Results:

  • Adenosine was found to induce DNA hypomethylation by interfering with the transmethylation pathway.
  • Inhibition of DNA methylation demonstrated efficacy in suppressing epileptogenesis across various seizure models.
  • Epileptic rat brains exhibited increased hippocampal DNA methylation, correlated with elevated DNA methyltransferase activity, disrupted adenosine homeostasis, and spontaneous seizures.
  • Adenosine therapy via silk implants reversed DNA hypermethylation, reduced mossy fiber sprouting, and prevented epilepsy progression for at least 3 months.

Conclusions:

  • Pathological alterations in DNA methylation homeostasis are implicated in the development of epilepsy.
  • Adenosine augmentation therapy can reverse these epigenetic changes, offering a promising approach to halt epilepsy progression.
  • Targeting epigenetic mechanisms represents a novel therapeutic avenue for managing epilepsy.